William G. Gavin

Production of goats by somatic cell nuclear transfer

In this study, we demonstrate the production of transgenic goats by nuclear transfer of fetal somatic cells. Donor karyoplasts were obtained from a primary fetal somatic cell line derived from a 40-day transgenic female fetus produced by artificial insemination of a nontransgenic adult female with semen from a transgenic male. Live offspring were produced with two nuclear transfer procedures. In one protocol, oocytes at the arrested metaphase II stage were enucleated, electrofused with donor somatic cells, and simultaneously activated. In the second protocol, activated in vivo oocytes were enucleated at the telophase II stage, electrofused with donor somatic cells, and simultaneously activated a second time to induce genome reactivation. Three healthy identical female offspring were born. Genotypic analyses confirmed that all cloned offspring were derived from the donor cell line. Analysis of the milk of one of the transgenic cloned animals showed high-level production of human antithrombin III, similar to the parental transgenic line.

Cloned Transgenic Offspring Resulting from Somatic Cell Nuclear Transfer in the Goat: Oocytes Derived from Both Follicle-Stimulating Hormone-Stimulated and Nonstimulated Abattoir-Derived Ovaries

Abstract The use of nuclear transfer (NT) techniques to create transgenic offspring capable of producing valuable proteins may have a major impact on the pharmaceutical market. Our objective was to compare the in vivo developmental potential of NT embryos produced from the fusion of transgenic donor cells with cytoplasts prepared from either FSH-stimulated ovaries or nonstimulated abattoir-derived ovaries. Donor cells were prepared from a transgenic fetus carrying the gene for human antithrombin III as a marker and used within four to eight subpassages. Cells were serum deprived for 4 days prior to cytoplast transfer. Oocytes were enucleated by removing the metaphase plate using a DNA stain and epifluorescent illumination. Donor cells were fused to enucleated oocytes by electric pulse and then chemically activated. There was no difference in the number of transferable embryos produced from cytoplasts of FSH-stimulated ovaries or from the fusion of cytoplasts from abattoir ovaries, nor was there a difference in the number of pregnancies established per recipient with either treatment. All pregnancies from both groups culminated in the births of healthy female kids (five total). To our knowledge, this is the first report of cloned goats produced from NT using cytoplasts derived from abattoir ovaries.

CRYOPRESERVATION OF EPIDIDYMAL SPERM OBTAINED AT NECROPSY FROM GOATS

In the field of transgenic production, the ability to carry a males genetic contribution beyond its natural life span is remarkably important. The ability to successfully collect and cryopreserve sperm from the epididymis at necropsy may prove to be a useful technique for preserving valuable genes. Thirty-two bucks ranging in age from 13 days to 7 years were examined in this study and 25 had epididymal sperm extracted at necropsy. Seven bucks yielded clear fluid with no spermatozoa; all were under four months of age. Testes were removed from the scrotal sac, small lateral incisions made across the convoluted tubules, pressure applied to the tail of the epididymis and small droplets of sperm pipetted into equilibrated extender. The average initial analysis of wave motion (0 to 5, 5 being rapid wave motion), live/dead sperm percentage and acrosomal integrity of 25 fresh epididymal samples were 5.0, 92%, and 100%, respectively. By comparison, the same parameters obtained from 206 fresh ejaculated samples were 3.0, 86%, and 95%, respectively. After being cryopreserved in liquid nitrogen, one straw from each sample was thawed after 3 to 60 days of cryostorage. Results of post-thaw analysis of 25 cryopreserved epididymal sperm samples for live/dead percentage and acrosomal integrity were 82% and 84%, respectively. By comparison, results of post-thaw analysis of 206 cryopreserved ejaculated sperm samples for live/dead percentage and acrosomal integrity were 60% and 89%, respectively. To assess the competence of the frozen epididymal sperm, IVF and AI were performed. In parallel IVF experiments, 40% of the oocytes showed cleavage patterns, with 6% developing to the blastocyst stage using frozen epididymal sperm, while 37% of the oocytes showed cleavage patterns and 4% developed into blastocysts using frozen ejaculated sperm. One artificial insemination out of 20 resulted in a pregnancy using frozen epididymal sperm, while 7 of 18 artificial inseminations resulted in a pregnancy using frozen ejaculated sperm. This data documents the successful collection and cryopreservation of epididymal sperm from the goat and its use for in vitro fertilization and artificial insemination.

Adeno-associated virus (AAV)-mediated transduction of male germ line stem cells results in transgene transmission after germ cell transplantation

We explored whether exposure of mammalian germ line stem cells to adeno‐associated virus (AAV), a gene therapy vector, would lead to stable transduction and transgene transmission. Mouse germ cells harvested from experimentally induced cryptorchid donor testes were exposed in vitro to AAV vectors carrying a GFP transgene and transplanted to germ cell‐depleted syngeneic recipient testes, resulting in colonization of the recipient testes by transgenic donor cells. Mating of recipient males to wild‐type females yielded 10% transgenic offspring. To broaden the approach to nonrodent species, AAV‐transduced germ cells from goats were transplanted to recipient males in which endogenous germ cells had been depleted by fractionated testicular irradiation. Transgenic germ cells colonized recipient testes and produced transgenic sperm. When semen was used for in vitro fertilization (IVF), 10% of embryos were transgenic. Here, we report for the first time that AAV‐mediated transduction of mammalian germ cells leads to transmission of the transgene through the male germ line. Equally important, this is also the first report of transgenesis via germ cell transplantation in a nonrodent species, a promising approach to generate transgenic large animal models for biomedical research.—Honaramooz, A., Megee, S., Zeng, W., Destrempes, M.M., Overton, S.A., Luo, J., Galantino‐Homer, H., Modelski, M., Chen, F., Blash, S., Melican, D. T., Gavin, W. G., Ayres, S., Yang, F., Wang, P. J., Echelard, Y., Dobrinski, I. Adeno‐associated virus (AAV) ‐mediated transduction of male germ line stem cells results in transgene transmission after germ cell transplantation. FASEB J. 22, 374–382 (2008)

Development of goat embryos after in vitro fertilization and parthenogenetic activation by different methods

Effective activation protocols that can be used during nuclear transfer investigations in goats need to be developed. We compared the development of IVF goat embryos with those of nonfertilized parthogenetically developing oocytes activated by treatment with either ionomycin or ethanol, both followed by immediate exposure to 6-diethylaminopurine (6-DMAP). Cumulus oocyte complexes (COCs) recovered from abattoir goat ovaries were either matured in a conventional laboratory incubator or placed in pre-equilibrated maturation medium and shipped overnight in a battery-operated dry incubator to another laboratory. Mature COCs were allocated randomly to one of three treatment groups. Group 1 oocytes (n=169 shipped, n=253 not shipped) were fertilized in vitro at 24 h postmaturation (hpm). The remaining COCs were activated at 28 hpm in either ionomycin (Group 2: n=362 shipped, n=202 not shipped), or ethanol (Group 3: n=263 shipped, n=249 not shipped). Activated oocytes were immediately incubated in 6-DMAP for 4 h. Blastocyst development was evaluated on Day 8 post-insemination/activation. Percent cleavage was comparable in shipped and nonshipped oocytes and in all treatment groups. In both shipped and nonshipped oocytes, parthenotes developing from ionomycin- and ethanol-activated oocytes had significantly greater blastocyst development (P<0.01) compared to IVF embryos (28.5 +/- 3.0, 27.4 +/- 2.8, 10.3 +/- 3.0, respectively for the nonshipped oocytes and 9.9 +/- 2.1, 10.3 +/- 2.4, 3.7 +/- 4.7 respectively for the shipped oocytes). Shipped oocytes had lower blastocyst development compared to nonshipped oocytes in the three treatment groups. The mean blastocyst cell number was not statistically different between shipped and nonshipped oocytes or among treatment groups, suggesting that all were equally viable.

Viable transgenic goats derived from skin cells.

The current study was undertaken to evaluate the possibility of expanding transgenic goat herds by means of somatic cell nuclear transfer (NT) using transgenic goat cells as nucleus donors. Skin cells from adult, transgenic goats were first synchronized at quiescent stage (G0) by serum starvation and then induced to exit G0 and proceed into G1. Oocytes collected from superovulated donors were enucleated, karyoplast–cytoplast couplets were constructed, and then fused and activated simultaneously by a single electrical pulse. Fused couplets were either co-cultured with oviductal cells in TCM-199 medium (in vitro culture) or transferred to intermediate recipient goat oviducts (in vivo culture) until final transfer. The resulting morulae and blastocysts were transferred to the final recipients. Pregnancies were confirmed by ultrasonography 25–30 days after embryo transfer. In vitro cultured NT embryos developed to morulae and blastocyst stages but did not produce any pregnancies while 30% (6/20) of the in vivo derived morulae and blastocysts produced pregnancies. Two of these pregnancies were resorbed early in gestation. Of the four recipients that maintained pregnancies to term, two delivered dead fetuses 2–3 days after their due dates, and two recipients gave birth to healthy kids at term. Fluorescence in situ hybridization (FISH) analysis confirmed that both kids were transgenic and had integration sites consistent with those observed in the adult cell line.

Hormonal induced lactation in transgenic goats

Abstract The aim of this study was to hormonally induce lactation in prepubertal, nulliparous, and male goats both transgenic and non‐transgenic. Analysis of milk quality, recombinant protein expression levels, total amount of recombinant protein produced, and the affect on long‐term reproductive capability was assessed. Fifty‐one goats (Saanen, Alpine, and Toggenburg), male and non‐pregnant females, 2‐31 months of age, either non‐transgenic or transgenic were evaluated with a total of 10 transgenes (constructs) represented. Animals were given estradiol (0.25 mg/kg, IM) and progesterone (0.75 mg/kg, IM) on days 1, 3, 5, 7, 9, 11 and 13, while prednisilone (0.4 mg/kg, IM) was administered on days 14‐16 with mammary massage occurring daily from day 5 onward. Forty of 51 animals, (36 of 38 females and 4 of 13 males) produced milk with total volumes in the 30‐day experiment, ranging from 20 μl to 530 mls per day, or approximately 500 ul to 6.8 liters total. Milk composition was analyzed for various parameters (total protein, fat content, total solids and somatic cell count) with no significant differences found between induced and natural milk. Expression levels of recombinant proteins from transgenic animals that were analyzed during the induced lactation, and subsequently during normal lactations, were found to have no significant differences. Total amount of recombinant protein produced was evaluated at different expression levels with no statistical significance seen. While over 90% of the females placed in the regimen became pregnant, there was a correlation between increased age at time of induction and an increase in number of breedings, or reproductive cycles needed to establish a pregnancy after induction. For males, 100% placed in the regimen settled females after hormonal induction of lactation. Semen quality was evaluated prior to, during, and after hormonal treatments. Semen volume and sperm number did not differ; however, for a small percentage of males, there was a decrease in sperm and post thaw motility after hormonal treatments. These levels returned to normal within 4‐5 weeks. Subsequent natural lactations showed total milk volumes within breed standards. These findings indicate that hormonal induction of lactation in the caprine species is a viable alternative to pregnancy for initiating lactation and milk production, does not adversely impact reproductive performance long‐term, and can benefit the early assessment of recombinant proteins produced in a transgenic founder program.

Non-viral transfection of goat germline stem cells by nucleofection results in production of transgenic sperm after germ cell transplantation†

Germline stem cells (GSCs) can be used for large animal transgenesis, in which GSCs that are genetically manipulated in vitro are transplanted into a recipient testis to generate donor‐derived transgenic sperm. The objectives of this study were to explore a non‐viral approach for transgene delivery into goat GSCs and to investigate the efficiency of nucleofection in producing transgenic sperm. Four recipient goats received fractionated irradiation at 8 weeks of age to deplete endogenous GSCs. Germ cell transplantations were performed 8–9 weeks post‐irradiation. Donor cells were collected from testes of 9‐week‐old goats, enriched for GSCs by Staput velocity sedimentation, and transfected by nucleofection with a transgene construct harboring the human growth hormone gene under the control of the goat beta‐casein promoter (GBC) and a chicken beta‐globin insulator (CBGI) sequence upstream of the promoter. For each recipient, transfected cells from 10 nucleofection reactions were pooled, mixed with non‐transfected cells to a total of 1.5 × 108 cells in 3 ml, and transplanted into one testis (n = 4 recipients) by ultrasound‐guided cannulation of the rete testis. The second testis of each recipient was removed. Semen was collected, starting at 9 months after transplantation, for a period of over a year (a total of 62 ejaculates from four recipients). Nested genomic PCR for hGH and CBGI sequences demonstrated that 31.3% ± 12.6% of ejaculates were positive for both hGH and CBGI. This study provides proof‐of‐concept that non‐viral transfection (nucleofection) of primary goat germ cells followed by germ cell transplantation results in transgene transmission to sperm in recipient goats. Mol. Reprod. Dev. 79: 255–261, 2012.

Update on the first cloned goats

229 6. 1000 Genomes Project Consortium. Nature 467, 1061–1073 (2010). 7. Chen, K. et al. Nat. Methods 6, 677–681 (2009). 8. Ye, K. et al. Bioinformatics 25, 2865–2871 (2009). 9. Abyzov, A. et al. Genome Res. 21, 974–984 (2011). 10. Lam, H.Y.K. et al. Nat. Biotechnol. 28, 47–55 (2010). 11. Danecek, P. et al. Bioinformatics 27, 2156–2158 (2011). 12. Quinlan, A.R. & Hall, I.M. Bioinformatics. 26, 841– 842 (2010). 13. Mills, R.E. et al. Nature 470, 59–65 (2011). 14. Wang, K., Li, M. & Hakonarson, H. Nucleic Acids Res. 38, e164 (2010). 15. Ng, P.C. & Henikoff, S. Annu. Rev. Genomics Hum. Genet. 7, 61–80 (2006). 16. Ramensky, V., Bork, P. & Sunyaev, S. Nucleic Acids Res. 30, 3894–3900 (2002). 17. Sanders, S.J. et al. Neuron 70, 863–885 (2011). 18. Ashley, E.A. et al. Lancet 375, 1525–1535 (2010). Yale University, New Haven, Connecticut, USA. 3Department of Molecular Biophysics and Biochemistry, Yale University, New Haven, Connecticut, USA. 4Department of Computer Science, Yale University, New Haven, Connecticut, USA. 5Present address: Personalis, Inc., Palo Alto, California, USA. e-mail: mpsnyder@stanford.edu

Transgenic Cloned Goats and the Production of Recombinant Therapeutic Proteins

The clinical use of recombinant therapeutic proteins has increased significantly during the last few decades. However, therapeutic indications often require large amounts of highly purified product, especially for therapies that call for chronic dosing regimes. The development of very efficient expression systems is essential to the full exploitation of the recombinant technology, so that life-saving medicines will become more readily available. Transgenic production technology is a highly scalable, capital-sparing approach to the manufacturing of complex recombinant proteins. ATryn®, recombinant antithrombin purified from the milk of transgenic goats, the first transgenically-derived therapeutic protein to gain regulatory approval, is currently approved in the United States and the EU for the treatment of Hereditary Antithrombin Deficiency. In addition, production of additional recombinant proteins in the milk of transgenic goats and rabbits is currently being tested for the production of a number of therapeutic antibodies as well as an alternative to plasma fractionation for the manufacture of human plasma proteins. The following review examines the potential of somatic cell nuclear transfer to generate transgenic goats used in the production of human recombinant therapeutics.